title: Assessment of the effects of zoledronic Acid therapy on bone metabolic indicators in hormone-resistant prostate cancer patients with bone metastatasis.
abstract: Purpose. Assessment of effects of zoledronic acid therapy on bone metabolic indicators in hormone-resistant prostate cancer patients with bone metastasis. Material and Methods. Hormone-resistant prostate cancer patients who were identified to have metastases in their bone scintigraphy were taken to trial group. Before administration of zoledronic acid, routine tests for serum calcium, total alkalen phosphates were studied. Sample sera for bone metabolic indicators BALP, PINP, and ICTP were collected. Bone pain was assessed via visual analogue scale and performance via Karnofsky performance scale. Four mg zoledronic acid was administered intravenously once a month. Results. When serum levels of bone forming indicators PINP; BALP were compared before and after therapy, there were insignificant decreases (P = .33, P = .21, resp.). Serum levels of bone destruction indicator ICTP was compared, and there was a significant decrease after zoledronic acid therapy (P = .04). When performances of the patients were compared during therapy period, performances decreased significantly due to progress of illness (P = .01). All patients had ostalgia caused by bone metastases at various degrees. Significant decrease in pain scores was observed (P < .01). Conclusion. Zoledronic acid therapy decreased bone destruction and was effective in palliation of pain in patient with bone metastasis. Using bone metabolic indicators during followup of zoledronic acid therapy might be useful.
authors.affiliation: Department of Urology, Erciyes University Faculty of Medicine, Kayseri, Turkey.
authors.forename: Abdullah
authors.initials: A
authors.lastname: Demirtas
authors.forename: Nurettin
authors.initials: N
authors.lastname: Sahin
authors.forename: Mehmet
authors.initials: M
authors.lastname: Caniklioglu
authors.forename: Mustafa
authors.initials: M
authors.lastname: Kula
authors.forename: Oguz
authors.initials: O
authors.lastname: Ekmekcioglu
authors.forename: Atila
authors.initials: A
authors.lastname: Tatlisen
references.citation: Br J Cancer. 2000 Feb;82(4):858-64
references.pmid: 10732759
references.citation: Breast Cancer Res. 2002;4(1):30-4
references.pmid: 11879557
references.citation: Oncologist. 2004;9 Suppl 4:14-27
references.pmid: 15459426
references.citation: Drugs. 2001;61(15):2177-92
references.pmid: 11772129
references.citation: Oncologist. 2005 Jan;10(1):52-62
references.pmid: 15632252
references.citation: Eur J Cancer. 1998 Feb;34(2):252-9
references.pmid: 9741329
references.citation: J Bone Miner Res. 1996 Mar;11(3):337-49
references.pmid: 8852944
references.citation: BJU Int. 2003 Nov;92(7):690-4
references.pmid: 14616447
references.citation: J Natl Cancer Inst. 2002 Oct 2;94(19):1458-68
references.pmid: 12359855
references.citation: BMC Nucl Med. 2004 Dec 04;4(1):3
references.pmid: 15579208
references.citation: Pain. 1997 Jan;69(1-2):1-18
references.pmid: 9060007
references.citation: Clin Chim Acta. 2003 May;331(1-2):45-53
references.pmid: 12691863
references.citation: Cancer Metastasis Rev. 2001;20(3-4):333-49
references.pmid: 12085970
references.citation: Cancer Treat Rev. 2003 Jun;29(3):189-98
references.pmid: 12787713
references.citation: Cochrane Database Syst Rev. 2002;(2):CD002068
references.pmid: 12076438
references.citation: J Urol. 1997 Feb;157(2):439-44
references.pmid: 8996327